Sentence examples for expression in this trial from inspiring English sources

Patients' breast tumours were not assessed for MUC1 expression in this trial; however, we have found that more than 90% of breast cancers express MUC1, and so it is likely that most of the patients were positive for MUC1 expression [ 3, 4].

The adipocyte fatty acid binding protein (AFABP) is known to contain PPRE binding sites in its upstream promoter region (23, 24) and 2% CLA did increase AFABP gene expression (Fig. 2) in this trial by 26% (P < 0.05).

EGFR expression in tumour tissue in this trial was determined by immunohistochemistry; however, the optimal biomarker for the selection of patients with NSCLC for treatment with EGFR inhibitors remains to be determined.

In this trial, EGFR expression was also evaluated by immunohistochemistry, and a correlation between EGFR expression and longer progression-free and overall survival was suggested (P=0.008 and P=0.08, respectively).

The same team further correlated serum levels of sE-cad with protein expression in a trial of 116 patients [ 39]: the sE-cad was found as an independent factor predicting long-term survival, with 90% of patients with a serum level of sE-cad > 10,000 ng/mL having a survival time < 3 years.

In this trial, the expression of EGFR family members was also examined by IHC in archival tumours and there was no association of EGFR family member expression level and clinical outcome.

In this trial, a liver-specific promoter was used to drive expression of the F9 transgene.

In this trial, the authors found a correlation between histone hyperacetylation and pretreatment HDAC2 expression.

As discussed before, in this trial, learners used strategy to pose the problem by directly using the given numerical expression, "8 3".

Nonetheless, it is conceivable that the presence of empty rAAV capsids might have contributed in some way to the successful gene expression in the SJCRH/UCL trial.

On the other side, it has to be emphasised that our study remains the only available study assessing the predictive role of ERCC1 IHC expression in a randomised trial with a non-cisplatin control arm.